Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations (Q40440921)

20 September 2017

Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations (English)

1 reference

inflammatory breast cancer

20 September 2017

0 references

1 reference

based on heuristic

inferred from title

comprehensive genomic profiling

1 reference

6

Juliann Chmielecki

1 reference

20 September 2017

Jeffrey S Ross

1

1 reference

20 September 2017

Siraj M Ali

2

1 reference

20 September 2017

Kai Wang

3

1 reference

20 September 2017

Depinder Khaira

4

1 reference

20 September 2017

Norma A Palma

5

1 reference

20 September 2017

Gary A Palmer

7

1 reference

20 September 2017

Deborah Morosini

8

1 reference

20 September 2017

Julia A Elvin

9

1 reference

20 September 2017

Sandra V Fernandez

10

1 reference

20 September 2017

Vincent A Miller

11

1 reference

20 September 2017

Philip J Stephens

12

1 reference

20 September 2017

Massimo Cristofanilli

13

1 reference

20 September 2017

language of work or name

English

0 references

publication date

12 October 2015

1 reference

Breast Cancer Research and Treatment

20 September 2017

1 reference

20 September 2017

154

1 reference

20 September 2017

1

1 reference

20 September 2017

155-162

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-015-3592-z

20 September 2017

0 references

cites work

Inflammatory breast cancer: what we know and what we need to learn

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Inflammatory carcinoma of the breast.A Pathologic Definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

High incidence of HER-2 positivity in inflammatory breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Inflammatory breast cancer: the disease, the biology, the treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Clinical outcome and prognosis of patients with inflammatory breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Genomic profiling of inflammatory breast cancer: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

How to apply de Bruijn graphs to genome assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

MYC in breast tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

BET bromodomain inhibition of MYC-amplified medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Selective inhibition of tumor oncogenes by disruption of super-enhancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Evolving novel anti-HER2 strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Activating HER2 mutations in HER2 gene amplification negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

The FGF/FGFR axis as a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3592-Z

10.1007/S10549-015-3592-Z

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference